Medicus Pharma Ltd.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
MDCX$1.83-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| General and administrative | $7,653,116 | $4,536,367 |
| Research and development | 3,527,786 | 193,578 |
| Total operating expenses | 11,180,902 | 4,729,945 |
| Loss from operations | (11,180,902) | (4,729,945) |
| Other (income) expense | ||
| Finance (income) expense, net | (25,386) | 584,820 |
| Total other (income) expense | (25,386) | 584,820 |
| Net loss and comprehensive loss for the year | (11,155,516) | (5,314,765) |
| Net loss per share attributable to common shareholders - basic and diluted | (1.16) | (1.53) |
| Weighted average number of common shares outstanding - basic and diluted | 9,619,184 | 3,479,494 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.